APH.TO - Aphria Inc.

Toronto - Toronto Delayed Price. Currency in CAD
12.32
+0.38 (+3.18%)
As of 12:59PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close11.94
Open12.45
Bid12.31 x 0
Ask12.32 x 0
Day's Range12.06 - 12.49
52 Week Range5.14 - 24.75
Volume5,097,894
Avg. Volume4,303,606
Market Cap2.589B
Beta4.06
PE Ratio (TTM)59.81
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • CNW Group6 hours ago

    Aphria Applauds Passage of Bill C-45, a Historic Milestone for Canada and the Cannabis Industry

    Vic Neufeld, CEO of Aphria, said, "This is a historic milestone for our industry and for our country that will reverberate around the world as Canada solidifies its progressive leadership on cannabis. "Today also represents an important milestone for our business, for which all of us at Aphria have been eagerly awaiting," said Neufeld. Backed by our annualized production capacity of 255,000 kg by early next year, we are well prepared to the meet the anticipated demand in the adult-use market while continuing to serve the ongoing needs of our medical cannabis patients.

  • Aphria Appoints Former Southern Glazer's Executive Joel Toguri as Vice President of Sales
    CNW Group5 days ago

    Aphria Appoints Former Southern Glazer's Executive Joel Toguri as Vice President of Sales

    LEAMINGTON, ON, June 15, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced the appointment of Joel Toguri as Vice President of Sales effective on June 18, 2018. Mr. Toguri joins the Company from Southern Glazer's of Canada ("Southern Glazer's"), where he was Vice President of Sales and Operations since 2013.

  • CNW Group12 days ago

    Aphria Welcomes Passage of Bill C-45 in Senate, Ready to Meet Demand for Adult-Use Cannabis in Canada

    Vic Neufeld, CEO of Aphria, said, "Today's passage of Bill C-45 through the Senate is a historic milestone towards safe and legal recreational cannabis in Canada. "While we share the government's goal to create a highly regulated market, we want to ensure that the cannabis industry is well positioned to responsibly meet the needs of Canadians and effectively compete with the black market, which is operating and marketing unbound by ethical or regulatory considerations.

  • CNW Group13 days ago

    IIROC Trade Resumption - SMU.UN; PL; ZYME; APH; NVU.UN

    TORONTO , June 7, 2018 /CNW/ - Trading resumes in: Company: SUMMIT INDUSTRIAL INCOME REIT UNITS TSX Symbol: SMU.UN (All Issues) Resumption (ET): 8:00 AM   Company: Pinnacle Renewable Holdings Inc. TSX ...

  • GlobeNewswire14 days ago

    Aphria Announces $225 Million Bought Deal

    Aphria Inc. (“Aphria” or the “Company”) (APH.TO) is pleased to announce that it has entered into an agreement with Clarus Securities Inc., on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a “bought deal” basis, 18,987,400 Common Shares (the “Common Shares”) of the Company at a price of C$11.85 per Common Share (the “Offering Price”) for aggregate gross proceeds to the Company of C$225,000,690 (the “Offering”).

  • CNW Group14 days ago

    IIROC Trading Halt - APH

    TORONTO , June 6, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Aphria Inc. TSX Symbol: APH (all issues) Reason: Pending News Halt Time (ET): 3:16 PM IIROC can make a decision to ...

  • CNW Group14 days ago

    Aphria to build state-of-the art Extraction Centre of Excellence

    LEAMINGTON, ON, June 6, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that the company's Board of Directors approved a $55 million capital project to build a state-of-the-art Extraction Centre of Excellence in Leamington, ON. Construction of the new Extraction Centre of Excellence is expected to begin immediately and the facility is scheduled to release its first concentrates by March 2019. Vic Neufeld, CEO of Aphria, said, "The Extraction Centre of Excellence will give Aphria a significant competitive advantage in cannabis concentrates, which are expected to be a significant product category.

  • ACCESSWIRE15 days ago

    Today's Research Reports on Resverlogix, Aphria, IMV and Oncolytics Biotech

    NEW YORK, NY / ACCESSWIRE / June 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • CNW Group23 days ago

    Aphria Forms Landmark Venture with South African Company Verve Group of Companies

    The Venture will focus on expanding the Company's footprint in established regulated cannabis markets in Africa. LEAMINGTON, ON, May 28, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has entered into a series of agreements (the "Transaction") resulting in Aphria forming a joint venture, CannInvest Africa Ltd. ("CannInvest"), with South African company Verve Group of Companies ("VGC"). As part of this transaction CannInvest will acquire an interest in Verve Dynamics Inc. ("Verve"), a licensed producer of medical cannabis extracts in Lesotho.  The Transaction is valued at C$4.05 million.

  • CNW Grouplast month

    Aphria's German subsidiary, Nuuvera Deutschland, acquires interest in Berlin-based Shöneberg Hospital

    LEAMINGTON, ON, May 17, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that its wholly-owned subsidiary Nuuvera Deutschland GmbH ("Deutschland") has acquired a 25.1% interest in Berlin-based Schöneberg Hospital ("Schöneberg" or the "Hospital"). The acquisition facilitates Deutschland's long-term strategy to educate German physicians and patients and advance evidence that supports the effectiveness of medical cannabinoids.

  • Business Wirelast month

    Aphria Selects Great North Distributors, a Canadian Subsidiary of Southern Glazer’s Wine & Spirits, for Canada-Wide Distribution of Adult-Use Cannabis

    Aphria Inc. (“Aphria” or the “Company”) (TSX: APH and US OTC: APHQF) and Great North Distributors, Inc. (“Great North Distributors”), a wholly-owned Canadian subsidiary of Southern Glazer’s Wine & Spirits (“Southern Glazer’s”) dedicated to the representation of cannabis products, are pleased to announce today that they have signed an agreement for Great North Distributors to serve as exclusive manufacturer’s representative for Aphria’s adult-use cannabis products throughout Canada, following the legalization of recreational cannabis for adult-use anticipated later this year.

  • CNW Grouplast month

    Aphria selects Great North Distributors, a Canadian subsidiary of Southern Glazer's Wine & Spirits, for Canada-wide distribution of adult-use cannabis

    LEAMINGTON, ON and TORONTO, May 17, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) and Great North Distributors, Inc. ("Great North Distributors"), a wholly-owned Canadian subsidiary of Southern Glazer's Wine & Spirits ("Southern Glazer's") dedicated to the representation of cannabis products, are pleased to announce today that they have signed an agreement for Great North Distributors to serve as exclusive manufacturer's representative for Aphria's adult-use cannabis products throughout Canada, following the legalization of recreational cannabis for adult-use anticipated later this year.

  • GlobeNewswirelast month

    Scythian Biosciences Announces ColCanna SAS’ Receipt of Licence to Cultivate and Import CBD into Colombia

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that Colombian-based ColCanna SAS (“ColCanna”), a company that Scythian is in the process of acquiring, has received a licence for the cultivation and importation of non-psychoactive cannabis (“CBD”) by the Ministry of Justice and Law of Colombia. Additionally, ColCanna has entered into an exclusive international supply agreement for Colombia (the “Supply Agreement”) with Aphria Inc. (APH.TO) (“Aphria”), a prominent Canadian low-cost producer of medical cannabis.

  • CNW Grouplast month

    Aphria signs exclusive agreement with Colombia-based Colcanna SAS to supply medical cannabis in Colombia

    LEAMINGTON, ON, May 16, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has signed an exclusive supply agreement with Colcanna SAS ("Colcanna") a Colombia-based pharmaceutical import and distribution company, which is licensed to import, sell and distribute medical cannabis, medical products and derivatives in Colombia. "We see tremendous potential for medical cannabis in several emerging markets, including Colombia," said Vic Neufeld, CEO of Aphria.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Oncolytics Biotech, CardioComm Solutions, BELLUS Health and Aphria

    NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • GlobeNewswire2 months ago

    Scythian Biosciences Corp. Announces the Appointment of European Cannabis Leader Rob Reid of Prohibition Partners as CEO

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) announced today that it has appointed Rob Reid as CEO, George Scorsis as Chairman of the Board of Directors and that it has reinstated Roger Rai to the Board of Directors effective April 25, 2018. In connection with these appointments, Jonathan Gilbert will be stepping down as CEO and will take on a new role of managing the University of Miami partnership. “I am extremely excited to be appointed as CEO of Scythian,” said Rob Reid.

  • CNW Group2 months ago

    Aphria Appoints Chief Commercial Officer and Chief Legal Officer Adding Depth to Leadership Team and Implements New Governance Initiatives

    LEAMINGTON, ON, April 25, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced the appointment of Jakob Ripshtein as the Company's first Chief Commercial Officer as of May 1, 2018 and Christelle Gedeon as Chief Legal Officer as of June 1, 2018. The Company is also announcing several new management appointments as Aphria continues to add depth, experience and leadership across the organization, together with the adoption of a formal governance policy regarding investments and other opportunities.

  • CNW Group2 months ago

    Aphria completes first medical cannabis shipment to Australia-based partner Althea

    LEAMINGTON, ON, April 24, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) announced today that its first shipment of medical cannabis to its Australian-based partner Althea Company Pty Ltd. ("Althea" or the "Australian Company") was received by Althea. The shipment is part of a previously announced agreement between Aphria and Althea, in which Aphria will provide the Australian Company with packaged co-branded cannabis oil and dried flower products for the Australian medical cannabis market.

  • CNW Group2 months ago

    Broken Coast Cannabis Nearly Doubles Production Capacity with Health Canada Approval of Phase III Expansion

    LEAMINGTON, ON, April 23, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that its subsidiary, Broken Coast Cannabis ("Broken Coast"), has received a license amendment from Health Canada that provides Broken Coast with an additional 18,000 square feet of production space as part of its Phase III expansion, bringing total production space to 44,000 square feet. "We're pleased to receive Health Canada approval on our Phase III expansion, which will enable us to quickly ramp up production of our small-batch, premium, high-quality B.C. bud," said John Moeller, Co-founder and President of Broken Coast.

  • GlobeNewswire2 months ago

    Scythian Announces ABP S.A.’s First Purchase Order with Aphria Inc.

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that Argentina-based ABP S.A. (“ABP”), a pharmaceutical import and distribution company that Scythian is in the process of acquiring, has received its first purchase order  (the “Order”) of CBD oil, which is to be fulfilled under the supply agreement with Aphria Inc. (APH.TO) (“Aphria”), a prominent Canadian producer of medical cannabis. The Order is for Aphria’s renowned CBD oil strain, Rideau.

  • CNW Group2 months ago

    Aphria Launches Solei, its First Adult-Use Brand, Designed for the Modern Cannabis Consumer

    LEAMINGTON, ON, April 17, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today introduced its first brand designed for Canada's new adult-use market, Solei Sungrown Cannabis ("Solei"). Solei has been designed to demystify cannabis and will enable current and novice users alike to control and enrich their cannabis journey, pairing an assortment of carefully curated products and strains with different experiences. Solei was created specifically for what will be one of the largest segments in the Canadian cannabis landscape, defined not by age, gender or geography, but rather by a shared mindset and attitude.

  • CNW Group2 months ago

    Aphria Inc. - Revenue Growth and Sub $1.00 Cash Cost per Gram Metric Highlight Quarter

    Tenth consecutive quarter of positive adjusted EBITDA 2 Significant levels of cash available for deployment in attractive investment opportunities LEAMINGTON, ON , April 16, 2018 /CNW/ - Aphria Inc. (" ...

  • CNW Group2 months ago

    Aphria to Announce Third Quarter Results on April 16, 2018

    LEAMINGTON, ON, April 10, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) will release its third quarter results for 2018 on April 16, 2018. Financial results are expected to be released at approximately 7:00am ET, through SEDAR and on Aphria's website at www.aphria.ca/investors. A conference call is scheduled for 9:00am ET and will feature a presentation by Aphria executives followed by a question and answer period with analysts.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Aphria, Titan Medical, ProMIS Neurosciences and Cardiome Pharma

    NEW YORK, NY / ACCESSWIRE / April 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group2 months ago

    Aphria provides update on Part III expansion operations

    "We're incredibly excited and proud of our whole team that has ramped up operations in our state-of-the-art Part III greenhouse expansion with incredible speed and care," said Vic Neufeld, CEO of Aphria. "As we prepare to make our first harvest from Part III later this month, work continues to rapidly advance on our 700,000-square-foot Part IV expansion, which we anticipate will have its first sale early next year.